@Article{,
AUTHOR = {Vladimir Ruzhynsky, Paul Whelan},
TITLE = {Management of a patient with locally advanced prostate cancer with degarelix: a case report},
JOURNAL = {Canadian Journal of Urology},
VOLUME = {20},
YEAR = {2013},
NUMBER = {3},
PAGES = {6808--6810},
URL = {http://www.techscience.com/CJU/v20n3/61617},
ISSN = {1488-5581},
ABSTRACT = {Gonadotropin releasing hormone (GnRH) antagonists, 
such as degarelix, are emerging as an androgen deprivation 
therapy primary agents in a treatment of advanced prostate 
cancer. The role of GnRH antagonists in management of 
lower urinary tract symptoms associated with prostate 
cancer has not been clearly established. In this report, we 
describe the case of a patient with locally advanced prostate 
cancer who presented with symptoms of urinary retention 
and renal failure. The use of degarelix in this patient led 
to a rapid reduction in the prostate-specific antigen level; 
however, obstructive symptoms persisted despite the use 
of degarelix and radiation treatment.},
DOI = {}
}